CAS: 31883-05-3; Moricizine

该化合物是一种抗心律药物,主要用于治疗某些类型的非正常心跳,特别是心血管不全,它属于被称为I类抗心律的药物类别,通过阻塞心脏细胞中的钠管而起作用,从而稳定心膜膜和减少易感性能.Moricizine的特点是它能够延长心脏耐寒期和降低心电速度.它通常通过口服,在肝脏中代谢,其药用动力受肝功能和伴随药物等因素的影响.常见副作用可能包括眩晕,疲劳和胃肠扰动.由于它有可能造成腹部效应,因此在治疗期间对心脏功能进行仔细监测至关重要.Moricizine的使用随着新的抗心律药剂的出现而下降,这些药能提高了安全性特征和功效.与任何药物一样,它对于在医疗专业指导下使用Moricizine至关重要,考虑到个别的病人因素和潜在的药物相互作用.

结构式图片

MSDS等安全信息

    上下游产品

    Ethyl <10-(1-Oxo-2-Propenyl)-10H-Phenothiazin-2-Yl> Carbamate 94989-94-3

    合成工艺路线路线简述

      Ethyl <10-(1-Oxo-2-Propenyl)-10H-Phenothiazin-2-Yl> Carbamate,吗啉 以55%的收率获得产物
      参考文献:Gritsenko,A. N.;Skoldinov,A. P.,Xim.-Farmats. Zh.,1986,20,N 4,485-488
      标题:Gritsenko,A. N.;Skoldinov,A. P.,Xim.-Farmats. Zh.,1986,20,N 4,485-488

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-9550000-B2
      优先权日:2011-09-09
      标题 :Compositions, methods, and systems for the synthesis and use of imaging agents
      发明人:ROBINSON SIMON P; YU MING
      权利人:ROBINSON SIMON P; YU MING; LANTHEUS MEDICAL IMAGING INC
      摘要:The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

      专利号:US-10814013-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:AU-2007308022-A2
      优先权日:2006-10-05
      标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:AU-2007308022-A1
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:US-2008107598-A1
      优先权日:2006-10-05
      标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
      丹东医创药业有限责任公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.ddycyy.com
      电话: 0415-3125313/0415-3124267👤
      📞丹东医创药业有限责任公司 ⚠️参考联系方式

      销售电话:0415-3125313/0415-3124267
      邮箱:
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      丹东前进药业材料有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.qianjinchina.com
      电话: 0415-28273002827303👤
      📞丹东前进药业材料有限公司 ⚠️参考联系方式

      销售电话:0415-28273002827303
      邮箱:44151188@163.com
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      地址:中国 辽宁 丹东市元宝区 蛤蟆塘大街1112号
      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Zou T, Chen Q, Chen C, Liu G, Ling Y, Pang Y, Xu Y, Cheng K, Zhu W, Wang RX, Qian LL, Ge J. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. J Thorac Dis. 2022 Jun;14(6):2187-2200. doi: 10.21037/jtd-22-534.
      2: Han C, Wirianto M, Kim E, Burish MJ, Yoo SH, Chen Z. Clock-Modulating Activities of the Anti-Arrhythmic Drug Moricizine. Clocks Sleep. 2021 Jun 22;3(3):351-365. doi: 10.3390/clockssleep3030022.
      3: Abalakov GA, Sutyagin PV. Moricizine (Ethmozine) Can Break Electrical Coupling between Rat Right Atrial Working Cardiomyocytes In Vitro. Bull Exp Biol Med. 2018 Jul;165(3):351-355. doi: 10.1007/s10517-018-4168-9. Epub 2018 Jul 12. 41(10):785. Chinese. 26(1 Pt 1):110-1. doi: 10.1046/j.1460-9592.2003.00160.x. 38(3):131-41. doi: 10.1016/s1537-1891(02)00213-6. 66(4):190-8. doi: 10.1159/000065533. 87(2):172-7. doi: 10.1016/s0002-9149(00)01311-4. 29(9):945-55. doi: 10.1080/004982599238182. 39(8):817-25. doi: 10.1177/00912709922008489. 27(2):217-29. doi: 10.1080/004982597240703. Erratum in: Xenobiotica 1999 Sep;29(9):969. 36(12):1161-8. doi: 10.1002/j.1552-4604.1996.tb04171.x. 57(1):31-5. doi: 10.1016/s0167-5273(96)02763-5. 19(1):82-9. doi: 10.1111/j.1540-8159.1996.tb04794.x. 9(5):715-22. doi: 10.1007/BF00878555. 35(10):1016-9. doi: 10.1002/j.1552-4604.1995.tb04019.x. 17(6):415-21. 48(1):59-65. doi: 10.1016/0167-5273(94)02220-d. 663(1):172-6. doi: 10.1016/0378-4347(94)00413-y. 90(6):2843-52. doi: 10.1161/01.cir.90.6.2843.

      合成参考文献


      参考文献:10.1007/s11920-004-0065-1
      摘要:Jiang W, Krishnan RR. Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease Curr Psychiatry Rep. 2004 Jun;6(3):202–9. doi: 10.1007/s11920-004-0065-1.
      参考文献:10.2165/00003495-200868050-00004
      摘要:Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68(5):607–30. doi: 10.2165/00003495-200868050-00004.
      摘要:Fomina IG, Iankin VV. [Prospective course of therapy arresting attacks of atrial fibrillation in patients with preexcitation syndromes]. Klin Med (Mosk). 1992 Feb;70(2):37–40.
      摘要:King SY, Powel RJ, Wong YN, Davidson AF, Vincent DR, Quon CY, Pieniaszek HJ. Effects of multiple doses of moricizine hydrochloride on its pharmacokinetics and hepatic microsomal enzymes in rats. Res Commun Chem Pathol Pharmacol. 1992 Mar;75(3):259–74.
      摘要:Xie JT, Li CL. Induction and termination of afterdepolarizations and triggered arrhythmias by drugs in cat heart in vivo. Methods Find Exp Clin Pharmacol. 1992 Jun;14(5):347–54.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知